Evolution of the Average Target: Sanofi

Data source: Sanofi(SAN)
Evolution of the Average Target - Sanofi

Evolution of the Target Price: Sanofi

Data source: Sanofi(SAN)
Evolution of the Target Price - Sanofi

Changes in Analyst Recommendations: Sanofi

Data source: Sanofi(SAN)
095b7dd832ebef131aca3183ca926a1.PjpjsFt84qARRWXwAOaZZr3LOA4PcE7xyZmamMgxhAw.DE47iQo-kcMpEhOmMp_wDJCjV29QKHrC-Onwq4oFyGsNTCmGbxKm-kcaNA~d4f39ffffa516cb4ebeecd397957ac46
10-07 Sanofi : Jefferies keeps its Buy rating ZD
10-07 Sanofi : JP Morgan sticks Neutral ZD
10-07 Berenberg Says Sanofi, Regeneron's Expanded Immunology Collaboration Extends 'Dominance' in Atopic Diseases MT
10-06 Sanofi : Berenberg remains its Buy rating ZD
10-01 Sanofi : RBC sticks Neutral ZD
10-01 Sanofi : JP Morgan reiterates its Neutral rating ZD
10-01 Sanofi to invest up to $8bn to expand alliance with Regeneron Zonebourse
10-01 Sanofi : Buy rating from Jefferies ZD
09-29 Regeneron Needs 'Better' Terms in Sanofi Renegotiation, RBC Says MT
09-29 Sanofi : Buy rating from Deutsche Bank ZD
09-17 Sanofi : UBS reiterates its Neutral rating ZD
09-15 Sanofi : Deutsche Bank reiterates its Buy rating ZD
09-14 Sanofi : Deutsche Bank reiterates its Buy rating ZD
09-09 RBC Capital Markets Begins Sanofi's Coverage at Sector Perform MT
09-09 RBC Initiates Sanofi at Sector Perform With EUR80 Price Target MT
09-09 RBC Launches Sanofi Coverage at Sector Perform Amid Management Turnaround, 'Light' Near-term Catalysts MT
09-09 Sanofi : From a Buy to Neutral rating by RBC ZD
09-08 Sanofi : Barclays is Neutral ZD
09-02 Sanofi : Gets a Buy rating from Deutsche Bank ZD
09-01 Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says MT
08-25 Sanofi : Deutsche Bank reiterates its Buy rating ZD
08-24 Sanofi : Berenberg gives a Buy rating ZD
08-24 Berenberg Keeps Sanofi at Buy Ahead of Asthma Drug Phase 2b Trial Results MT
08-24 Berenberg Still Rates Sanofi a Buy Zonebourse
08-20 Cancer vaccines finally garner the spotlight Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+12.79%
+7.03%
+2.22%
+8.54%
+5.14%
+4.76%
+31.69%
-4.73%
+5.43%
Average +8.10%
Weighted average by Cap. +8.64%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
71.60EUR
Average target price
93.56EUR
Spread / Average Target
+30.67%
High Price Target
107.20EUR
Spread / Highest target
+49.72%
Low Price Target
78.00EUR
Spread / Lowest Target
+8.94%

Analyst Consensus Detail

Analyst consensus - Sanofi

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Sanofi
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Sanofi